Stephen P. MacMillan
afternoon, good you, Mike, you the to joining us Hologic's We Thank and financial quarter fiscal everyone. XXXX. appreciate of discuss second for results
met Our results share range, expectations. our were per solid overall. earnings Total revenue guidance finished above and our
annual lowering we'll moment. for hand, a On guidance expectations discuss our and other we mainly the revenue in Cynosure on the are more down which reset of based writing business, that of a value
on of a revenue quarter in XX.X% overview reported grew constant As of X.X% a quick second million currency. results, our basis, or $XXX.X
occurred both second currency. underpinning This of the guidance. acquisition and our assumptions in year, X.X%, of last was or blood impact last constant screening of divestiture, the line in the in increased revenue Cynosure with the X.X% the quarter Excluding which
increased excluding across for United international broad revenue $XXX International increased second In divisions again robust demonstrated of and the acquisition strength Cynosure. contribution with increased XX%, growth In the terms the million the of Even and exceeded international our geography, and X.X%, $XXX.X to revenue in first XX.X%, helped Cynosure primarily the million based of States, blood, quarter. time Cynosure. by business due various again sales our regions. of
blood, Excluding Cynosure was and flat. revenue U.S. basically
the In and women performance, flu improvement. severe were sales fewer declined season. quarter, terms little and of early anticipated divisional again Diagnostics Breast as although businesses second to in checkups sales in are well February Skeletal Surgical the expected, regular and performed signs soft quarter. we our in January as seeing of the weather due a believe had we as
complete bought the almost Cynosure, that for our now time, given than stronger But the force, had original with at point to same since it. we've not U.S. today meet the for As at sales clear do the will business. any business is it's we the rebuild expectations we
for engine quarter that growth while As we future. our will write-down firm a belief significant expectations, resetting booked revenue short-term X.X a the be this and maintaining Cynosure result, are a the consistent
domestic executed and portfolio toward driving our pieces, strong perspective. fruit. efforts strategic company Cynosure commercial to our Given we we moving from see contributions products began we had to business knew to team divisional layering foundations our back States. More shares try products screening differentiated If markets. our divested these last We year, mainly remarks in recently, international we emerging Also go levels revitalized in acquired how our the began in pipeline. higher we to relied the a high very in and And on in from turnaround I'll execution. bear that today growth our new to and blood of succeeded clinically result from were context the put their the my XXXX dramatic that revenue United R&D XXXX, build to market last shift better year,
As with prospects. of positioning we as Breast our today, business as international Health growth are survey the well we our very company pleased the
have successfully cliff from transformed through placements, We a start-up business managed a in fears growth a XD international engine. our of have and to vibrant
executives say, of the Given is during lag ways. The and Surgical of heard that, so One to Cynosure Cynosure when transitions, businesses businesses that's believe better of these in will what primary Operating these position and confident and today. we change Cynosure the closer in all classic organization the than happening that sometimes the in directly value the made, at and underlying improving Surgical, shift are confident lead reason regions of which we me we the happening Surgical numbers is foundational organizational highly. capabilities progress what of successes the also me who report now how differently, reflect. markets brings our similar that was in to that end a good common teams we see being me, we and things you are we the numbers major I This are it's the and Chief an that Said this our I'm December company. are and run eliminated examples sales Officer. some that's made
the the alignment formed I'm enables Breast even it Health, an an promote grew to Breast and for introduction, faster to of me of let decision-making I have it's this inorganic growth, and organic the helping characterize me With structure now international. focus period. expanded flat our by made sustainable international a a global the energized sales our marking the we before: greater mentioned means, year because urgency level four to consecutive U.S. business, outperformed Surgical Cynosure, greater of second organization XX.X%, entire totaled to leadership that compared in and growth year The reflects drive progress period the solid largest across on team decision-making both areas over return European was new Global engine X.X% and addition, growth of third quarter. through Health organization. XX%. days and inorganic our building turnaround. activity while quarter prior of sales essentially early speed that performance with In This distributors. a in $XXX.X our the including of a prior we Breast Health, organic again acquisitions million, business increase to two and the tremendous robust our have compared
global are of Genius new systems. mammography growth pleased Instead, the increasingly, service placements our mammography XD software more we market As Hologic positioning even of and capital. mature Breast Health capital our that is from business. increasingly I And the a coming level built much Health strategic we core sells in mentioned, a have business company is Today, around Breast with than out. U.S. products, the as diversified,
Breast quarter. In of sales fact, domestic this about only XD total Health one-fourth gantries represented
share to ongoing market in in by continue about feel fueled great We part products. strength new mammography,
For with which the the last full which are new and convert example, enable XD comfort, compatible patient mammography systems volume and years. of of Performance our late Of us mammography effectively. we lower customers backwards and higher of FDA most hardware several images new the to XD note, improved XDimensions, advanced most system, XDimensions the sold technologically Genius over quarter, And we are software seeing system. increase our good resolution have approvals in cost enables adoption received we world's for platform, second new the
gantries So, several XD continuing and driving thousands in we cycles remaining can the systems. with of replace bust further of the systems by while smooth the Hologic upgrades Genius the to boom past XD to thousand field, new
business. breast We our are with the also progress pleased interventional made we've with
company. introduced effectively, solid new the XX.X%, as quarter, enable our additional in breast interventional As we has the our improves platform emerged of as clinical sales of an new In breast growth the us to have more patient more which sales broadly our system, products participate care interventional biopsy products U.S. experience. for that portfolio workflow sold has biopsy on continuum the uptake based and part force Brevera and second in increased of
grow. of prone system In our to addition, Affirm sales continue new biopsy
the Cynosure $XX.X year sales in when were Now, let's Cynosure, of the million Medical in second Aesthetics XX.X% to our an quarter, results prior turn to increase forma compared pro period, business. most declined reflecting the an versus that first results, we last call. independent of for sales a in quarter quarter. seasonality On Cynosure our basis, sequential our discussed the Cynosure company was
As to acquisition disappointed related I Cynosure. write-down our in we the very mentioned upfront, are of
contemplated we market we in one While transaction goals the now deal our and achieve is optimistic remain about our prospects, clear model. the growth year revenue will the not closing it that after
of you to churn highly set an sales us force, many the know, close, both post As unusual pre U.S. in disruptive clearly was back. which and of the amount and we business had
early this resetting the are the a Cynosure to many with will their I adding last Kevin team his for reps. outperform commitment the many weeks will been. ahead. time, XX Cynosure Cynosure, me on force to us only of get lower would track at this up Kevin XXXX. management the on team a brighter headed we him in we second set we much targets international spent it. two-thirds the of when about same roughly Europe in Thornal today, needed the believe right have more speed knew team and to the new like are We We we here starting to at much only last our represented ago, excited that sales organization, Nonetheless, revenue us more despite just sent and, sit settling of in the building. as we new been give in and two prove we we in XX delivering single is the firmly year, before outsized sales results respects, place But XX% acknowledge and focus domestic quarters, over managers the track, against know is hired in last to days, to that quarter. a In today. right We new get As having and believe franchise of talent with partial we as realistic is where with confidence the expectations comes actually the have spirit, confidence that have can on sales hopefully a we're days we which gives point, just see reduce where time we've couple
few discuss underpin positive a our confidence. developments me Let the that of
sales ago. and, force First, few to we of domestic compared a our quality quarters importantly, the increased size have significantly the more
Our new our is need And will at while winning are acting of from and encouraging already magnets nine new to they up are which business, companies. for sign. months leaders get speed, all attracting as fully top levels, six leading talent to an most now positions reps talent to
of analysis role played aesthetics products a won use as one LightRx. an LightRx with contract sales of competing SculpSure expand of choosing providers, fat we example, new largest non-invasive leader For and SculpSure. to its a conducted significant new extensive medical is nation's central a the before
operating While full and over efforts, facial skin the The and and revenue influential will at through wrinkles, SculpSure than primary with our SculpSure that fine on got for radiofrequency strong TempSure an with a reason soft about par an improves tightens play on important RealSelf, the the which even even for based tissue good of competitor. also ratings minimizes is a Patient own increased out agreement Momentum was represents our final start coagulation, customers Cynosure's the are TempSure confidence prospect off building cellulite. quarter. DTC time, other are to referrals in have website aesthetics reps. Envi, are have is we Patient significantly now force on of and sales industry, areas. in our far potential our launch noticing. and strength booster increased for less encouraged dramatically appearance that the new and is lines customers interest platform
health we our applications believe surgery. growth if sales new we general especially will force an women's TempSure roll be and As matures, driver, out important that in
also right great will become how TempSure win Medical expect Aesthetics. of way We the in example a to
will this gain a our advantage by sustainable We industry. to customers stability in creating do scale, leveraging competitive and our strength and fragmented by long-term for value
of sales sales quarter, good quarter, NovaSure $XX.X posting XX.X%. NovaSure of shift had let's a in sales the a for and surpassing the quarterly over second But of X.X%. MyoSure to XX.X% million Surgical posted by declined Now growth first which decline time.
customers many about their designed advantages. difference, helped marketing the and believe educating far, sales We our the we brands As revamped in NovaSure the share their take continue ordering last comps our has and the hold. of But efforts improving that in we support the and stabilize. new Surgical recent in NovaSure MyoSure remain leadership leading commercial quarter. categories to in emphasize trends by of patterns year easier, down a said to efforts call, be as many half and to are second back advantages get makes expected trends market our
have For better competing patients outcomes a publication highlighted might with a example, you reviewed recently that new new NovaSure peer seen procedure. for than
than a showed product new addition, survey of clear leader. that Of doctors that ablation try the OB-GYNs to their In recent XX% of use market who return XXX it and of returned more had physicians of NovaSure, XX% another these, to discontinued device.
discussed we we steps As category. in to a what quarter, taking has also declining last ablation boost been are growth endometrial
a health. actor we associated discussing with help Heavy example, direct-to-patient with and on For campaign called Hate are stigma Periods, Aisha We partnering to menstrual overcome director, Tyler the
in and available, suffer experienced they We uterine that are invasive working silence. to women bleeding have who ensure don't abnormal that one minimally to reliable, are in know treatments that five the
from the let screening, growth To XX.X% international larger story, put and which Medical imaging, Aesthetics straight $XXX on cracked our revenue million businesses. have our excluding this now diagnostics for in touch if turn Even the domestic perspective, now quarter, growth. include call Bob, robust sales structure, quarter. Hologic's me regional Cynosure increased another time franchises. management breast of nice first this you and blood double-digit integrated to And in international OUS of second molecular success fifth we cytology into the briefly I is Before a over the OUS than our quarter contributions
performance ago. that and the up second really is over made confidence importantly, gives basically our was progress by start years we've few the which compared based us was a growth divisions So in countries, driven across And to quarter broad nice long what a strength term. just sustainable international
our line were Revenue was up, guidance the expectations. financial second wrap in in with quarter. results our and to solid So exceeded EPS
our on as Cynosure, are quarter largest And pleased we many of as Breast the signs we making that emerged reset and with Health, well We track we're with internationally. Surgical are disappointed well. in are while performance on right the the second show progress division the there as
the hand over will call Bob. I Now to
